Life
Regulatory Scrutiny Intensifies for Psychedelic Biotechs Amid Acquisition Moves
Psychedelic biotech companies are facing increased regulatory scrutiny, coinciding with acquisition efforts from Biogen and Eli Lilly, while Gilead faces criticism from Doctors Without Borders.
Editorial Staff
1 min read
Recent developments indicate a heightened regulatory focus on psychedelic biotech firms, particularly concerning their promotional strategies on platforms like YouTube.
In parallel, major pharmaceutical players Biogen and Eli Lilly are actively pursuing acquisitions, potentially reshaping the landscape of the biotech sector.
Additionally, Doctors Without Borders has voiced significant concerns regarding Gilead's practices, adding another layer of scrutiny to the industry.